Treatment patterns and outcomes of different subtypes of metastatic breast cancer patients in a Swedish real world setting with a focus on HER2-/HR+ subtype

被引：0
|
作者：
Lindman, H.
Szilcz, M.
Freilich, J.
Carlqvist, P.
Vertuani, S.
Anell, B.
Holm, B.
机构：
[1] Uppsala Univ, Uppsala, Sweden
[2] Novartis Oncol Nord, Taby, Sweden
[3] PAREXEL Int, Stockholm, Sweden
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P1-16-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-16-10
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study
    Mycock, Katie
    Zhan, Lin
    Hart, Kieran
    Taylor-Stokes, Gavin
    Milligan, Gary
    Atkinson, Christian
    Mitra, Debanjali
    FUTURE ONCOLOGY, 2021, 18 (03) : 349 - 362
  • [42] Real-world treatment patterns and clinical outcomes among women with HR+/HER2-advanced or metastatic breast cancer treated in real-world settings in Italy and Germany
    De laurentiis, Michelino
    Harbeck, Nadia
    Law, Ernest
    Ajmera, Mayank
    Mitra, Debanjali
    Davis, Keith
    Brucker, Sara
    De Placido, Sabino
    CANCER RESEARCH, 2020, 80 (04)
  • [43] Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
    Geneviève Gauthier
    Patrick Gagnon-Sanschagrin
    Annie Guérin
    Rebecca Burne
    Tania Small
    Polly Niravath
    Anand A. Dalal
    Advances in Therapy, 2018, 35 : 503 - 514
  • [44] Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2-metastatic breast cancer
    Goyal, Ravi K.
    Carter, Gebra Cuyun
    Nagar, Saurabh P.
    Smyth, Emily N.
    Price, Gregory L.
    Huang, Yu-Jing
    Li, Li
    Davis, Keith L.
    Kaye, James A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (10) : 1699 - 1710
  • [45] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
    Robert, Nicholas
    Chen, Connie
    Doan, Justin
    Venkatasetty, Divea
    Espirito, Janet L.
    Aguilar, Kathleen M.
    FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
  • [46] Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States
    Giovanni Zanotti
    Matthias Hunger
    Julia J Perkins
    Ruslan Horblyuk
    Monique Martin
    BMC Cancer, 17
  • [47] Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review
    Martorana, Federica
    Sano, Maria Vita
    Valerio, Maria Rosaria
    Fogli, Stefano
    Vigneri, Paolo
    Danesi, Romano
    Gebbia, Vittorio
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2024, 15
  • [48] Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2-metastatic breast cancer in the real-world setting
    Luhn, P.
    O'Hear, C.
    Ton, T. G.
    Sanglier, T.
    Hsieh, A.
    Oliveri, D.
    Chuo, J.
    Xiao, Y.
    Emens, L.
    CANCER RESEARCH, 2019, 79 (04)
  • [49] Addition of Ribociclib to Endocrine Therapy Improves Outcomes in EarlyStage, HR+/HER2- Breast Cancer
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 352 - 352
  • [50] Real-world treatment patterns for HER2+and HR+/HER2-advanced breast cancer in county areas of China
    Ji, Y.
    Qu, H.
    Zhou, F.
    Ren, Y.
    Liang, W.
    Wang, J.
    Dai, G.
    Liu, M.
    Luo, J.
    Wu, Q.
    Tan, X.
    Meng, Q.
    He, W.
    Liu, W.
    Hu, G.
    Wang, J.
    Tang, H.
    Gao, J.
    Liu, H.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1424 - S1425
12345